Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-03-23

Clinical Trial Update: Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation [NA]

View source ↗

Summary

A randomized double-blind trial evaluating ranolazine for new-onset atrial fibrillation was terminated; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ranexa (ranolazine)

Snippet

Sponsor: Northwell Health | Conditions: Atrial Fibrillation New Onset, Hemorrhage | NA | Status: TERMINATED | Results posted: 2017-03-23